Halozyme Therapeutics Surges to 151st in Trading Volume Despite 24.56% Stock Price Drop

On May 13, 2025, Halozyme Therapeutics (HALO) experienced a significant surge in trading volume, with a total of $712 million in shares traded, marking a 311.86% increase from the previous day. This surge placed Halozyme at the 151st position in terms of trading volume for the day. However, despite the high trading volume, the stock price of Halozyme Therapeutics fell by 24.56%.

Halozyme Therapeutics' stock rating was downgraded to Underperform by Leerink Partners. This revision in the stock outlook is primarily due to new draft guidance from the Centers for Medicare & Medicaid Services (CMS) regarding drug pricing. The CMS draft guidance suggests that the pricing of certain drug combinations may be affected, which could impact Halozyme's revenue and market position.

Investors and analysts are closely monitoring the situation, as the CMS draft guidance could have significant implications for Halozyme's future performance. The company's stock has been volatile in recent months, and the latest downgrade and CMS guidance have added to the uncertainty surrounding its prospects. Halozyme Therapeutics will need to navigate these challenges carefully to maintain investor confidence and continue its growth trajectory.